The FDA has approved lerodalcibep (Lerochol – Lib Therapeutics), a subcutaneously injected proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lerodalcibep is the fourth subcutaneously injected PCSK9-directed therapy to be approved in the US; the monoclonal antibodies alirocumab (Praluent) and evolocumab (Repatha) and the small interfering RNA inclisiran (Leqvio) were approved earlier (see Table 3).
- Leucovorin for Cerebral Folate Deficiency
- In Brief: Wegovy HD – High-Dose Injectable Semaglutide for Weight Loss
- In Brief: RSV Vaccine (Arexvy) for Ages 18-49
- In Brief: Vybrique — Sildenafil Oral Film for Erectile Dysfunction
- Relacorilant (Lifyorli) for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (online only)
RELEASE
The FDA has approved Widaplik (Azurity), a fixed-dose combination of the angiotensin receptor blocker (ARB) telmisartan, the dihydropyridine calcium channel blocker amlodipine, and the thiazide-like diuretic indapamide, for treatment of hypertension in adults. Telmisartan, amlodipine, and indapamide are also available alone and in various combinations for treatment of hypertension. Two other three-drug combinations containing an ARB, amlodipine, and hydrochlorothiazide (Exforge HCT and Tribenzor) have been available for years for treatment of hypertension (see Table 1).1
STANDARD TREATMENT ― A thiazide or thiazide-like diuretic, an angiotensin-converting enzyme (ACE) inhibitor or ARB, and a long-acting dihydropyridine calcium channel blocker, alone or in two-drug combinations, is generally recommended for initial treatment of hypertension. Most patients require …